In vitro cancer cell-ECM interactions inform in vivo cancer treatment

Advanced Drug Delivery Reviews

Volumn 97, Issue , 2016, Pages 270-279

  Holle, Andrew W ^a   Young, Jennifer L ^a   Spatz, Joachim P ^a,b  

^a MAX PLANCK INSTITUTE FOR INTELLIGENT SYSTEMS   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemoresistance; Chemotherapy; Extracellular matrix (ECM); Ligands; Metastasis; Tumor microenvironment

Indexed keywords

BIOMIMETIC PROCESSES; BIOMIMETICS; CHEMOTHERAPY; CYTOLOGY; DIAGNOSIS; DISEASES; ENZYME ACTIVITY; ENZYME INHIBITION; LIGANDS; SAFETY TESTING; SCAFFOLDS (BIOLOGY); TUMORS;

BIOMIMETIC SCAFFOLDS; CHEMORESISTANCE; EXTRACELLULAR MATRICES; IN-VITRO MODELS; IN-VITRO TESTING; METASTASIS; MICROENVIRONMENTS; TUMOR MICROENVIRONMENT;

CELLS;

ABCIXIMAB; ABITUZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CILENGITIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETARACIZUMAB; FLUOROURACIL; FRESOLIMUMAB; IMATINIB; INTETUMUMAB; IRINOTECAN; MELPHALAN; MUPARFOSTAT; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; PACLITAXEL; PREDNISONE; SB 265123; SCH 221153; SD 983; SM 256; THALIDOMIDE; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLOCIXIMAB; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; CELL FUNCTION; CELL INTERACTION; CELL SURVIVAL; COLON CANCER; DEGRADATION; DRUG TARGETING; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE TUMOR; REVIEW; RIGIDITY; SHEAR STRESS; SOLID TUMOR; SYNTHESIS; TISSUE PRESSURE; TISSUE SCAFFOLD; TOPOGRAPHY; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; EXTRACELLULAR MATRIX; HUMANS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84957823778     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.10.007     Document Type: Review

References (209)

1. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8:193-204.
2. Norden A.D., Drappatz J., Wen P.Y. Antiangiogenic therapies for high-grade glioma. Nat. Rev. Neurol. 2009, 5:610-620.
3. Engler A.J., Sen S., Sweeney H.L., Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
4. Cavalcantiadam E., et al. Lateral spacing of integrin ligands influences cell spreading and focal adhesion assembly. Eur. J. Cell Biol. 2006, 85:219-224.
5. Kim D.-H., Provenzano P.P., Smith C.L., Levchenko A. Matrix nanotopography as a regulator of cell function. J. Cell Biol. 2012, 197:351-360.
6. Berrier A.L., Yamada K.M., Yamada K.M. Cell-matrix adhesion. J. Cell. Physiol. 2007, 213:565-573.
7. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
8. Wozniak M.A., Modzelewska K., Kwong L., Keely P.J. Focal adhesion regulation of cell behavior. Biochim. Biophys. Acta (BBA) - Mol. Cell Res. 2004, 1692:103-119.
9. Pathak A., Kumar S. Independent regulation of tumor cell migration by matrix stiffness and confinement. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:10334-10339.
10. Bauer A.L., Jackson T.L., Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput. Biol. 2009, 5.
11. Kim J., Hayward R.C. Mimicking dynamic in vivo environments with stimuli-responsive materials for cell culture. Trends Biotechnol. 2012, 30:426-439.
12. Shannon K.E., et al. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin. Exp. Metastasis 2004, 21:129-138.
13. Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. Breast 2013, 22:S66-S72.
14. Larsen M., Artym V.V., Green J.A., Yamada K.M., Yamada K.M. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr. Opin. Cell Biol. 2006, 18:463-471.
15. Allinen M., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
16. Bourboulia D., Stetler-Stevenson W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 2010, 20:161-168.
17. Hadler-Olsen E., Winberg J.-O., Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumor Biol. 2013, 34:2041-2051.
18. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
19. Tse J.R., Engler A.J. Preparation of Hydrogel Substrates with Tunable Mechanical Properties 2010, 10.16.1-10.16.16. John Wiley & Sons, Inc. 10.1002/0471143030.cb1016s47.
20. Zaari N., Rajagopalan P., Kim S.K., Engler A.J., Wong J.Y. Photopolymerization in microfluidic gradient generators: microscale control of substrate compliance to manipulate cell response. Adv. Mater. 2004, 16:2133-2137.
21. Peyton S.R., Putnam A.J. Extracellular matrix rigidity governs smooth muscle cell motility in a biphasic fashion. J. Cell. Physiol. 2005, 204:198-209.
22. Vincent L.G., Choi Y.S., Alonso-Latorre B., del Álamo J.C., Engler A.J. Mesenchymal stem cell durotaxis depends on substrate stiffness gradient strength. Biotechnol. J. 2013, 8:472-484.
23. Rowlands A.S., George P.A., Cooper-White J.J. Directing osteogenic and myogenic differentiation of MSCs: interplay of stiffness and adhesive ligand presentation. Am. J. Physiol. Cell Physiol. 2008, 295:C1037-C1044.
24. Huebsch N., et al. Harnessing traction-mediated manipulation of the cell/matrix interface to control stem-cell fate. Nat. Mater. 2010, 9:518-526.
25. Shih Y.-R.V., Tseng K.-F., Lai H.-Y., Lin C.-H., Lee O.K. Matrix stiffness regulation of integrin-mediated mechanotransduction during osteogenic differentiation of human mesenchymal stem cells. J. Bone Miner. Res. 2011, 26:730-738.
26. Ghosh K., et al. Cell adaptation to a physiologically relevant ECM mimic with different viscoelastic properties. Biomaterials 2007, 28:671-679.
27. Evans N.D., et al. Substrate stiffness affects early differentiation events in embryonic stem cells. Eur. Cell. Mater. 2009, 18:1-13. (discussion 13-4).
28. Marklein R.A., Burdick J.A. Spatially controlled hydrogel mechanics to modulate stem cell interactions. Soft Matter 2010, 6:136-143.
29. Engler A.J., Sen S., Sweeney H.L., Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
30. Saha K., et al. Substrate modulus directs neural stem cell behavior. Biophys. J. 2008, 95:4426-4438.
31. Holle A.W., Engler A.J. More than a feeling: discovering, understanding, and influencing mechanosensing pathways. Curr. Opin. Biotechnol. 2011, 22:648-654.
32. Pelham R.J., Wang Y.L. Cell locomotion and focal adhesions are regulated by the mechanical properties of the substrate. Biol. Bull. 1998, 194:348-349. (discussion 349-50).
33. Lekka M., et al. Elasticity of normal and cancerous human bladder cells studied by scanning force microscopy. Eur. Biophys. J. 1999, 28:312-316.
34. Cross S.E., Jin Y.-S., Rao J., Gimzewski J.K. Nanomechanical analysis of cells from cancer patients. Nat. Nanotechnol. 2007, 2:780-783.
35. Cross S.E., et al. AFM-based analysis of human metastatic cancer cells. Nanotechnology 2008, 19:384003.
36. Fuhrmann A., et al. AFM stiffness nanotomography of normal, metaplastic and dysplastic human esophageal cells. Phys. Biol. 2011, 8:015007.
37. Paccione R.J., et al. Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. Mol. Cancer Ther. 2008, 7:2894-2903.
38. Beil M., et al. Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells. Nat. Cell Biol. 2003, 5:803-811.
39. Krouskop T.A., Wheeler T.M., Kallel F., Garra B.S., Hall T. Elastic moduli of breast and prostate tissues under compression. Ultrason. Imaging 1998, 20:260-274.
40. Plewes D.B., Bishop J., Samani A., Sciarretta J. Visualization and quantification of breast cancer biomechanical properties with magnetic resonance elastography. Phys. Med. Biol. 2000, 45:1591-1610.
41. Paszek M.J., Weaver V.M. The tension mounts: mechanics meets morphogenesis and malignancy. J. Mammary Gland Biol. Neoplasia 2004, 9:325-342.
42. Levental K.R., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
43. Zhang D.Y., Friedman S.L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012, 56:769-775.
44. Paszek M.J., et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
45. Milosevic M., Fyles A., Hedley D., Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin. Radiat. Oncol. 2004, 14:249-258.
46. Fang M., Yuan J., Peng C., Li Y. Collagen as a double-edged sword in tumor progression. Tumor Biol. 2013, 35:2871-2882.
47. Erler J.T., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
48. Wozniak M.A., Desai R., Solski P.A., Der C.J., Keely P.J. ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J. Cell Biol. 2003, 163:583-595.
49. Ulrich T.A., Jain A., Tanner K., MacKay J.L., Kumar S. Probing cellular mechanobiology in three-dimensional culture with collagen-agarose matrices. Biomaterials 2010, 31:1875-1884.
50. Wolf K., et al. Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J. Cell Biol. 2013, 201:1069-1084.
51. Ulrich T.A., de Juan Pardo E.M., Kumar S. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res. 2009, 69:4167-4174.
52. Tokuda E.Y., Leight J.L., Anseth K.S. Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness. Biomaterials 2014, 35:4310-4318.
53. Soman P., et al. Cancer cell migration within 3D layer-by-layer microfabricated photocrosslinked PEG scaffolds with tunable stiffness. Biomaterials 2012, 33:7064-7070.
54. Zhang W., Choi D.S., Nguyen Y.H., Chang J., Qin L. Studying cancer stem cell dynamics on PDMS surfaces for microfluidics device design. Sci. Rep. 2013, 3.
55. Levental I., et al. A simple indentation device for measuring micrometer-scale tissue stiffness. J. Phys. Condens. Matter 2010, 22:194120.
56. Arnold M., et al. Activation of integrin function by nanopatterned adhesive interfaces. ChemPhysChem 2004, 5:383-388.
57. Chen C.S., Mrksich M., Huang S., Whitesides G.M., Ingber D.E. Geometric control of cell life and death. Science 1997, 276:1425-1428.
58. Maheshwari G., Brown G., Lauffenburger D.A., Wells A., Griffith L.G. Cell adhesion and motility depend on nanoscale RGD clustering. J. Cell Sci. 2000, 113(Pt 10):1677-1686.
59. Hersel U., Dahmen C., Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003, 24:4385-4415.
60. Jeschke B., et al. RGD-peptides for tissue engineering of articular cartilage. Biomaterials 2002, 23:3455-3463.
61. Harisi R., Jeney A. Extracellular matrix as target for antitumor therapy. Onco Targets Ther. 2015, 1387. 10.2147/OTT.S48883.
62. Blehm B.H., Jiang N., Kotobuki Y., Tanner K. Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma. Biomaterials 2015, 56:129-139.
63. Sherman-Baust C.A., et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003, 3:377-386.
64. Glass R., Möller M., Spatz J.P. Block copolymer micelle nanolithography. Nanotechnology 2003, 14:1153-1160.
65. Kruss S., Erpenbeck L., Schön M.P., Spatz J.P. Circular, nanostructured and biofunctionalized hydrogel microchannels for dynamic cell adhesion studies. Lab Chip 2012, 12:3285-3289.
66. Krishnamoorthy S., Hinderling C., Heinzelmann H. Nanoscale patterning with block copolymers. Mater. Today 2006, 9:40-47.
67. Graeter S.V., et al. Mimicking cellular environments by nanostructured soft interfaces. Nano Lett. 2007, 7:1413-1418.
68. Shahal T., Geiger B., Dunlop I.E., Spatz J.P. Regulation of integrin adhesions by varying the density of substrate-bound epidermal growth factor. Biointerphases 2012, 7:23-11.
69. Benton G., Crooke E., George J. Laminin-1 induces E-cadherin expression in 3-dimensional cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status. FASEB J. 2009, 23:3884-3895.
70. Teng Y., Qiu J., Zheng Y., Luo X., Zhang L. Effects of type I collagen and fibronectin on regulation of breast cancer cell biological and biomechanical characteristics. J. Med. Biol. Eng. 2014, 34:62-68.
71. Barney L.E., et al. A cell-ECM screening method to predict breast cancer metastasis. Integr. Biol. 2015, 7:198-212.
72. Benton G., Kleinman H.K., George J., Arnaoutova I. Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int. J. Cancer 2011, 128:1751-1757.
73. Albini A., et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47:3239-3245.
74. Kenny P.A., et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007, 1:84-96.
75. Benton G., Arnaoutova I., George J., Kleinman H.K., Koblinski J. Matrigel: from discovery and ECM mimicry to assays and models for cancer research. Adv. Drug Deliv. Rev. 2014, 79-80:3-18.
76. Han J., et al. Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput. Biol. 2010, 6.
77. Lam C.R.I., et al. A 3D biomimetic model of tissue stiffness interface for cancer drug testing. Mol. Pharm. 2014, 11:2016-2021.
78. Rolli C.G., Seufferlein T., Kemkemer R., Spatz J.P. Impact of tumor cell cytoskeleton organization on invasiveness and migration: a microchannel-based approach. PLoS ONE 2010, 5.
79. Tan P.H.S., Aung K.Z., Toh S.L., Goh J.C.H., Nathan S.S. Three-dimensional porous silk tumor constructs in the approximation of in vivo osteosarcoma physiology. Biomaterials 2011, 10.1016/j.biomaterials.2011.04.084.
80. Corall S., et al. \upalpha 5\upbeta 1-integrin and MT1-MMP promote tumor cell migration in 2D but not in 3D fibronectin microenvironments. Comput. Mech. 2014, 53:499-510.
81. Rape A.D., Kumar S. A composite hydrogel platform for the dissection of tumor cell migration at tissue interfaces. Biomaterials 2014, 35:8846-8853.
82. Biela S.A., Su Y., Spatz J.P., Kemkemer R. Different sensitivity of human endothelial cells, smooth muscle cells and fibroblasts to topography in the nano-micro range. Acta Biomater. 2009, 5:2460-2466.
83. Loesberg W.A., Walboomers X.F., van Loon J.J.W.A., Jansen J.A. The effect of combined hypergravity and micro-grooved surface topography on the behaviour of fibroblasts. - PubMed - NCBI. Cell Motil. Cytoskeleton 2006, 63:384-394.
84. Sidani M., Wyckoff J., Xue C., Segall J.E., Condeelis J. Probing the microenvironment of mammary tumors using multiphoton microscopy. J. Mammary Gland Biol. Neoplasia 2006, 11:151-163.
85. Provenzano P.P., et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008, 6:11.
86. Provenzano P.P., Inman D.R., Eliceiri K.W., Trier S.M., Keely P.J. Contact guidance mediated three-dimensional cell migration is regulated by Rho/ROCK-dependent matrix reorganization. Biophys. J. 2008, 95:5374-5384.
87. Petrie R.J., Doyle A.D., Yamada K.M. Random versus directionally persistent cell migration. Nat. Rev. Mol. Cell Biol. 2009, 10:538-549.
88. Wolf K., Friedl P. Extracellular matrix determinants of proteolytic and non-proteolytic cell migration. Trends Cell Biol. 2011, 21:736-744.
89. Sabeh F., Shimizu-Hirota R., Weiss S.J. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 2009, 185:11-19.
90. Wolf K., et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol. 2007, 9:893-904.
91. Milosevic M., et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res. 2001, 61:6400-6405.
92. Nathan S.S., et al. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin. Cancer Res. 2005, 11:2389-2397.
93. Aung K.Z., Pereira B.P., Tan P.H.S., Han H.C., Nathan S.S. Interstitial fluid pressure as an alternate regulator of angiogenesis independent of hypoxia driven HIF-1α in solid tumors. J. Orthop. Res. 2012, 30:2038-2045.
94. Nathan S.S., et al. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J. Orthop. Res. 2008, 26:1520-1525.
95. Khawar I.A., Kim J.H., Kuh H.-J. Improving drug delivery to solid tumors: priming the tumor microenvironment. J. Control. Release 2015, 201:78-89.
96. Berg A., Ekwall A.-K.H., Rubin K., Stjernschantz J., Reed R.K. Effect of PGE1, PGI2, and PGF2α analogs on collagen gel compaction in vitro and interstitial pressure in vivo. Am. J. Physiol. Heart Circ. Physiol. 1998, 274:H663-H671.
97. Mitchell M.J., King M.R. Computational and experimental models of cancer cell response to fluid shear stress. Front. Oncol. 2013, 3.
98. Kim J., Yu W., Kovalski K., Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 1998, 94:353-362.
99. Bockhorn M., Jain R.K., Munn L.L. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?. Lancet Oncol. 2007, 8:444-448.
100. Polacheck W.J., Charest J.L., Kamm R.D. Interstitial flow influences direction of tumor cell migration through competing mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:11115-11120.
101. Qazi H., Shi Z.-D., Tarbell J.M. Fluid shear stress regulates the invasive potential of glioma cells via modulation of migratory activity and matrix metalloproteinase expression. PLoS ONE 2011, 6.
102. Mitchell M.J., King M.R. Fluid shear stress sensitizes cancer cells to receptor-mediated apoptosis via trimeric death receptors. New J. Phys. 2013, 15:015008.
103. Ghosh K., et al. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11305-11310.
104. Trédan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
105. Mitsiades C.S., Mitsiades N.S., Munshi N.C., Richardson P.G., Anderson K.C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 2006, 42:1564-1573.
106. Vincent T., Mechti N. Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leuk. Lymphoma 2015, 46:803-811.
107. Sloan E.K., et al. Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006, 8:R20.
108. Chrenek M.A., Wong P., Weaver V.M. Tumour-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation. Breast Cancer Res. 2001, 3:224-229.
109. Morin P.J. Cancer Drug Resistance 2006, 201-210. Humana Press. 10.1007/978-1-59745-035-5_11. B. Teicher (Ed.).
110. Damiano J.S., Dalton W.S. Integrin-mediated drug resistance in multiple myeloma. Leuk. Lymphoma 2000, 38:71-81.
111. Jain R.K. Transport of Molecules, Particles, and Cells in Solid Tumors 2003, 1:241-263. 10.1146/annurev.bioeng.1.1.241.
112. Jang S.H., Wientjes M.G., Lu D., Au J.L.S. Drug delivery and transport to solid tumors. Pharm. Res. 2003, 20:1337-1350.
113. Kyle A.H., Huxham L.A., Yeoman D.M., Minchinton A.I. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin. Cancer Res. 2007, 13:2804-2810.
114. Tannock I.F. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br. J. Cancer 1968, 22:258-273.
115. Ljungkvist A.S.E., et al. Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:215-228.
116. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat. Rep. 1978, 62:1117-1133.
117. Graeber T.G., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours 1996, 379:88-91. (Published online: 04 January 1996). 10.1038/379088a0.
118. Kinoshita M., Johnson D.L., Shatney C.H., Lee Y.L., Mochizuki H. Cancer cells surviving hypoxia obtain hypoxia resistance and maintain anti-apoptotic potential under reoxygenation. Int. J. Cancer 2001, 91:322-326.
119. Kovacic P., Osuna J.A. Mechanisms of Anti-Cancer Agents Emphasis on Oxidative Stress and Electron Transfer 2000.
120. Gerweck L.E., Vijayappa S., Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 2006, 5:1275-1279.
121. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000, 60:2497-2503.
122. Heldin C.-H., Rubin K., Pietras K., Östman A. High interstitial fluid pressure |[mdash]| an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
123. Grantab R., Sivananthan S., Tannock I.F. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 2006, 66:1033-1039.
124. Wang X., Shah A.A., Campbell R.B., Wan K.-T. Glycoprotein mucin molecular brush on cancer cell surface acting as mechanical barrier against drug delivery. Appl. Phys. Lett. 2010, 97:263703.
125. Glinsky G.V. Anti-adhesion cancer therapy. Cancer Metastasis Rev. 1998, 17:177-185.
126. Juliano R.L., Varner J.A. Adhesion molecules in cancer: the role of integrins. Curr. Opin. Cell Biol. 1993, 5:812-818.
127. Carragher N.O., Frame M.C. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol. 2004, 14:241-249.
128. Zhao J., Guan J.-L. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009, 28:35-49.
129. Zhao X., Guan J.-L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev. 2011, 63:610-615.
130. Bommert K., Bargou R.C., Stühmer T. Signalling and survival pathways in multiple myeloma. Eur. J. Cancer 2006, 42:1574-1580.
131. Schlaepfer D.D., Hauck C.R., Sieg D.J. Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol. 1999, 71:435-478.
132. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell Adhesion Mediated Drug Resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-1667.
133. Sanz-Rodriguez F. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001, 97:346-351.
134. Chauhan D., et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2004, 103:3158-3166.
135. Kane R.C., Bross P.F., Farrell A.T., Pazdur R. Velcade ®: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8:508-513.
136. Yang H.H. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J. Clin. Oncol. 2003, 21:4239-4247.
137. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of. Cell 2003, 112:831-843.
138. Durie B.G.M., et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol. J. 2003, 4:379-398.
139. Grossman D., Altieri D.C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 2001, 20:3-11.
140. Ria R., et al. αvβ3 integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002, 87:836-845.
141. Sanz-Rodriguez F., Ruiz-Velasco N., Pascual-Salcedo D., Teixidó J. Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. Br. J. Haematol. 1999, 107:825-834.
142. Michigami T., et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity. Blood 2000, 96:1953-1960.
143. Uchiyama H., Barut B.A., Mohrbacher A.F., Chauhan D., Anderson K.C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993, 82:3712-3720.
144. Vincent T., Jourdan M., Sy M.S., Klein B., Mechti N. Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein. J. Biol. Chem. 2001, 276:14728-14736.
145. Driel M.V., et al. CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells. Leukemia 2002, 16:135-143.
146. Bergamaschi A., et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 2007, 214:357-367.
147. Farmer P., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 2009, 15:68-74.
148. Zuo W., et al. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. Mol. Med. Rep. 2011, 5:373-376.
149. Said G., et al. Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin. - PubMed - NCBI. Chemother. Res. Pract. 2012, 2012:1-10.
150. Misra S., Ghatak S., Toole B.P. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 2005, 280:20310-20315.
151. Misra S., Misra S., Ghatak S., Zoltan-Jones A., Toole B.P. Regulation of multidrug resistance in cancer cells by hyaluronan. J. Biol. Chem. 2003, 278:25285-25288.
152. Pupa S.M., et al. Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res. 2007, 67:4271-4277.
153. Berx G., Berx G., Van Roy F., Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res. 2001, 3:289-293.
154. Livant D.L., et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res. 2000, 60:309-320.
155. Stoeltzing O., et al. Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 2003, 104:496-503.
156. Khalili P., et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 2006, 5:2271-2280.
157. Cianfrocca M.E., et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer 2006, 94:1621-1626.
158. Doñate F., et al. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin. Cancer Res. 2008, 14:2137-2144.
159. Hersey P., et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010, 116:1526-1534.
160. Dechantsreiter M.A., et al. N-methylated cyclic RGD peptides as highly active and selective α Vβ 3integrin antagonists. J. Med. Chem. 1999, 42:3033-3040.
161. Stupp R., et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15:1100-1108.
162. Heidenreich A., et al. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 2013, 24:329-336.
163. Besse B., et al. Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann. Oncol. 2012, 24:mds281-mds296.
164. Élez E., et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann. Oncol. 2015, 26:132-140.
165. Reinmuth N., et al. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 2003, 63:2079-2087.
166. Mita M., et al. Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin. Cancer Res. 2011, 17:193-200.
167. Mitjans F., et al. In vivo therapy of malignant melanoma by means of antagonists of αv integrins. Int. J. Cancer 2000, 87:716-723.
168. Mahalingam B., et al. Atomic basis for the species-specific inhibition of αV integrins by monoclonal antibody 17E6 is revealed by the crystal structure of αVβ3 ectodomain-17E6 Fab complex. J. Biol. Chem. 2014, 289:13801-13809.
169. Carron C.P., et al. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. 1998, 58:1930-1935.
170. Kumar C. Integrin αvβ3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets 2003, 4:123-131.
171. Lorenzon G., et al. Abstract 1568: GLPG0187, a small molecule integrin antagonist, shows good safety and decrease in CTX levels in single ascending dose study. Cancer Res. 2014, 70:1568-1568.
172. ROBERTS A.B., HEINE U.I., Flanders K.C., SPORN M.B. Transforming growth factor-β. Ann. N. Y. Acad. Sci. 1990, 580:225-232.
173. Rice L.M., et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J. Clin. Invest. 2015, 125:2795-2807.
174. Trachtman H., et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-|[beta]| antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011, 79:1236-1243.
175. Morris J.C., et al. Phase I study of GC1008 (Fresolimumab): A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 2014, 9.
176. Stevenson J.P., et al. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. OncoImmunology 2013, 2.
177. Grütter C., et al. A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20251-20256.
178. Weber G.F. Why does cancer therapy lack effective anti-metastasis drugs?. Cancer Lett. 2013, 328:207-211.
179. Lu N., et al. Endostar suppresses invasion through downregulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Exp. Biol. Med. (Maywood) 2008, 233:1013-1020.
180. Xu M., et al. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone 2013, 57:111-115.
181. Sun Y., et al. Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer. Thorac. Cancer 2013, 4:440-448.
182. Nadir Y., Brenner B. Heparanase multiple effects in cancer. Thromb. Res. 2014, 133:S90-S94.
183. Liu C.-J., et al. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J. Gastroenterol. 2014, 20:11384-11393.
184. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 2011, 15:1013-1031.
185. Jeney A., et al. Glycosaminoglycans as novel target in antitumor therapy. Tokai J. Exp. Clin. Med. 1990, 15:167-177.
186. Thompson C.B., et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 2010, 9:3052-3064.
187. Eikenes L., Bruland Ø.S., Brekken C., Davies C.de L. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 2004, 64:4768-4773.
188. Taghian A.G., et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol. 2005, 23:1951-1961.
189. Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., Lee W.W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 1986, 12:1239-1242.
190. von Pawel J., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J. Clin. Oncol. 2000, 18:1351-1359.
191. Williamson S.K., et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J. Clin. Oncol. 2005, 23:9097-9104.
192. Hicks K.O., Pruijn F.B., Sturman J.R., Denny W.A., Wilson W.R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res. 2003, 63:5970-5977.
193. Lee C.M., Tannock I.F. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br. J. Cancer 2006, 94:863-869.
194. Liu J., et al. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 2014, 32:693-710.
195. June C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 2007, 117:1466-1476.
196. Germain R.N. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation. Cell 1994, 76:287-299.
197. Platzman I., Janiesch J.-W., Matić J., Spatz J.P. Artificial antigen-presenting interfaces in the service of immunology. Isr. J. Chem. 2013, 53:655-669.
198. Deeg J., et al. T cell activation is determined by the number of presented antigens. Nano Lett. 2013, 13:5619-5626.
199. Matić J., Deeg J., Scheffold A., Goldstein I., Spatz J.P. Fine tuning and efficient T cell activation with stimulatory aCD3 nanoarrays. Nano Lett. 2013, 13:5090-5097.
200. Platzman I., Janiesch J.-W., Spatz J.P. Synthesis of nanostructured and biofunctionalized water-in-oil droplets as tools for homing T cells. J. Am. Chem. Soc. 2013, 135:3339-3342.
201. Martino M.M., et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science 2014, 343:885-888.
202. Millard M., Odde S., Neamati N. Integrin targeted therapeutics. Theranostics 2011, 1:154-188.
203. Wang Y.L., Discher D.E. Cell Mechanics-Book 2007, Elsevier, (at http://www.worldcat.org/title/cell-mechanics/oclc/157028004).
204. Azarin S.M., et al. In vivo capture and label-free detection of early metastatic cells. Nat. Commun. 2015, 6:8094.
205. Klein K., Maier T., Hirschfeld-Warneken V.C., Spatz J.P. Marker-free phenotyping of tumor cells by fractal analysis of reflection interference contrast microscopy images. Nano Lett. 2013, 13:5474-5479.
206. Klein K., Rommel C.E., Hirschfeld-Warneken V.C., Spatz J.P. Cell membrane topology analysis by RICM enables marker-free adhesion strength quantification. Biointerphases 2013, 8:28.
207. Trikha M., et al. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 2002, 62:2824-2833.
208. Kerr J.S., et al. Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res. 1999, 19:959-968.
209. Kumar C.C., et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001, 61:2232-2238.